+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2020

  • ID: 4986876
  • Drug Pipelines
  • January 2020
  • Region: Global
  • 53 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Algobate AG
  • Mallinckrodt Plc
  • Shionogi & Co Ltd
  • MORE
Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2020

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2020, provides an overview of the Opioid-Induced Constipation (OIC) (Toxicology) pipeline landscape.

Opioids are effective pain relievers, but often have the side effect of constipation. These medicines affect the gastrointestinal tract in a variety of ways. Opioids increase the amount of time it takes stool to move through the gastric system. They increase non-propulsive contractions in the middle of the small intestine (jejunum) and decrease longitudinal propulsive peristalsis - motions critical to moving food through the intestines. This results in food that fails to travel through the digestive tract. Opioids are also able to partially paralyze the stomach (gastroparesis) so that food remains in the digestive organ for a longer period of time. Additionally opioids reduce digestive secretions and decrease the urge to defecate. Symptoms of OIC include feeling and being sick, tiredness and lethargy, appetite loss, feeling depressed.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Opioid-Induced Constipation (OIC) (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Opioid-Induced Constipation (OIC) (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Opioid-Induced Constipation (OIC) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 2, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Opioid-Induced Constipation (OIC) (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Opioid-Induced Constipation (OIC) (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Opioid-Induced Constipation (OIC) (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Opioid-Induced Constipation (OIC) (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Opioid-Induced Constipation (OIC) (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Opioid-Induced Constipation (OIC) (Toxicology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Opioid-Induced Constipation (OIC) (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Opioid-Induced Constipation (OIC) (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Algobate AG
  • Mallinckrodt Plc
  • Shionogi & Co Ltd
  • MORE
  • Introduction
  • Report Coverage
  • Opioid-Induced Constipation (OIC) - Overview
  • Opioid-Induced Constipation (OIC) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Opioid-Induced Constipation (OIC) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Opioid-Induced Constipation (OIC) - Companies Involved in Therapeutics Development
  • Algobate AG
  • Bausch Health Companies Inc
  • Mallinckrodt Plc
  • Shionogi & Co Ltd
  • Opioid-Induced Constipation (OIC) - Drug Profiles
  • dolcanatide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • lubiprostone - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • naldemedine tosylate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • naloxone hydrochloride PR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Opioid-Induced Constipation (OIC) - Dormant Projects
  • Opioid-Induced Constipation (OIC) - Discontinued Products
  • Opioid-Induced Constipation (OIC) - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
List of Tables
  • Number of Products under Development for Opioid-Induced Constipation (OIC), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Opioid-Induced Constipation (OIC) - Pipeline by Algobate AG, H1 2020
  • Opioid-Induced Constipation (OIC) - Pipeline by Bausch Health Companies Inc, H1 2020
  • Opioid-Induced Constipation (OIC) - Pipeline by Mallinckrodt Plc, H1 2020
  • Opioid-Induced Constipation (OIC) - Pipeline by Shionogi & Co Ltd, H1 2020
  • Opioid-Induced Constipation (OIC) - Dormant Projects, H1 2020
  • Opioid-Induced Constipation (OIC) - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Opioid-Induced Constipation (OIC), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Algobate AG
  • Bausch Health Companies Inc
  • Mallinckrodt Plc
  • Shionogi & Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll